Q3 EPS Estimates for Fractyl Health Raised by HC Wainwright

Key Points

• HC Wainwright raised its Q3 2026 EPS forecast for Fractyl Health to a loss of $0.13 per share from a projected loss of $0.14, while maintaining a Buy rating and $8 price target.
• Fractyl Health reported a quarterly loss of $0.12 per share, beating analysts’ consensus estimate of a $0.14 loss by $0.02. The stock opened at $0.70, near the lower end of its 52-week range.
• Analyst sentiment remains moderately bullish, with four Buy ratings, one Hold and one Sell, producing an average target price of $5.12. Company insiders also purchased 171,493 shares worth approximately $127,150 over the past 90 days.

Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Equities research analysts at HC Wainwright increased their Q3 2026 EPS estimates for Fractyl Health in a research note issued to investors on Tuesday, August 11th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.13) for the quarter, up from their previous forecast of ($0.14). HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Fractyl Health's current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Fractyl Health's Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.49) EPS and FY2027 earnings at ($0.36) EPS.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02.

A number of other brokerages have also recently issued reports on GUTS. Wall Street Zen raised shares of Fractyl Health from a "strong sell" rating to a "hold" rating in a research report on Saturday, May 16th. Craig Hallum initiated coverage on shares of Fractyl Health in a report on Wednesday, July 1st. They issued a "buy" rating and a $4.00 price objective for the company. Finally, Weiss Ratings lowered shares of Fractyl Health from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Fractyl Health presently has an average rating of "Moderate Buy" and an average target price of $5.12.

Fractyl Health Stock Down 0.8%

GUTS stock opened at $0.70 on Thursday. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $2.44. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The stock has a market capitalization of $110.79 million, a price-to-earnings ratio of -0.79 and a beta of 2.32. The business's fifty day moving average price is $0.76 and its two-hundred day moving average price is $0.68.

Institutional Trading of Fractyl Health

A number of institutional investors and hedge funds have recently made changes to their positions in GUTS. Jane Street Group LLC acquired a new stake in shares of Fractyl Health during the 2nd quarter worth approximately $31,000. Accredited Investors Inc. bought a new stake in Fractyl Health during the first quarter worth $46,000. Scientech Research LLC acquired a new stake in shares of Fractyl Health in the 3rd quarter valued at $49,000. FNY Investment Advisers LLC lifted its position in shares of Fractyl Health by 84.3% during the 2nd quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company's stock worth $51,000 after buying an additional 29,920 shares during the last quarter. Finally, Prelude Capital Management LLC acquired a new stake in Fractyl Health in the third quarter valued at about $55,000.

Insiders Place Their Bets

In related news, Director Ian Sheffield purchased 35,000 shares of the company's stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average price of $0.73 per share, with a total value of $25,550.00. Following the completion of the purchase, the director directly owned 35,000 shares in the company, valued at $25,550. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William Bradley purchased 68,493 shares of the company's stock in a transaction that occurred on Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, with a total value of $49,999.89. Following the purchase, the director owned 84,622 shares of the company's stock, valued at $61,774.06. This represents a 424.66% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 171,493 shares of company stock worth $127,150 in the last 90 days. 8.52% of the stock is owned by company insiders.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source